Delcath Systems (DCTH) Competitors $10.68 -0.45 (-4.04%) As of 01:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DCTH vs. NVCR, SSII, CDRE, BLFS, ESTA, MDXG, PLSE, INMD, IRMD, and BBNXShould you be buying Delcath Systems stock or one of its competitors? The main competitors of Delcath Systems include NovoCure (NVCR), SS Innovations International (SSII), Cadre (CDRE), BioLife Solutions (BLFS), Establishment Labs (ESTA), MiMedx Group (MDXG), Pulse Biosciences (PLSE), InMode (INMD), iRadimed (IRMD), and Beta Bionics (BBNX). These companies are all part of the "medical equipment" industry. Delcath Systems vs. Its Competitors NovoCure SS Innovations International Cadre BioLife Solutions Establishment Labs MiMedx Group Pulse Biosciences InMode iRadimed Beta Bionics NovoCure (NASDAQ:NVCR) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment. Do insiders and institutionals have more ownership in NVCR or DCTH? 84.6% of NovoCure shares are held by institutional investors. Comparatively, 61.1% of Delcath Systems shares are held by institutional investors. 5.5% of NovoCure shares are held by insiders. Comparatively, 17.4% of Delcath Systems shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has better earnings & valuation, NVCR or DCTH? Delcath Systems has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovoCure$605.22M2.27-$168.63M-$1.56-7.89Delcath Systems$37.21M10.04-$26.39M$0.05213.60 Is NVCR or DCTH more profitable? Delcath Systems has a net margin of 3.18% compared to NovoCure's net margin of -27.13%. Delcath Systems' return on equity of 6.91% beat NovoCure's return on equity.Company Net Margins Return on Equity Return on Assets NovoCure-27.13% -47.74% -13.79% Delcath Systems 3.18%6.91%5.80% Does the media prefer NVCR or DCTH? In the previous week, NovoCure had 10 more articles in the media than Delcath Systems. MarketBeat recorded 14 mentions for NovoCure and 4 mentions for Delcath Systems. NovoCure's average media sentiment score of 1.39 beat Delcath Systems' score of 1.34 indicating that NovoCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 10 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Delcath Systems 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend NVCR or DCTH? NovoCure currently has a consensus price target of $28.79, suggesting a potential upside of 133.94%. Delcath Systems has a consensus price target of $24.50, suggesting a potential upside of 129.40%. Given NovoCure's higher possible upside, equities research analysts clearly believe NovoCure is more favorable than Delcath Systems.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NovoCure 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57Delcath Systems 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, NVCR or DCTH? NovoCure has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. SummaryDelcath Systems beats NovoCure on 10 of the 15 factors compared between the two stocks. Get Delcath Systems News Delivered to You Automatically Sign up to receive the latest news and ratings for DCTH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DCTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DCTH vs. The Competition Export to ExcelMetricDelcath SystemsMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$372.54M$6.72B$5.80B$10.16BDividend YieldN/A1.23%5.69%4.61%P/E Ratio213.0026.0074.6226.00Price / Sales10.0463.48468.1791.50Price / CashN/A21.6337.0859.91Price / Book4.974.9912.156.30Net Income-$26.39M$176.38M$3.28B$270.75M7 Day Performance-8.33%1.04%1.13%3.33%1 Month Performance-1.84%3.25%7.44%6.49%1 Year Performance8.87%12.41%63.14%28.08% Delcath Systems Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DCTHDelcath Systems3.1576 of 5 stars$10.68-4.0%$24.50+129.4%+11.7%$372.54M$37.21M213.0060Positive NewsNVCRNovoCure4.3902 of 5 stars$12.60+2.6%$28.79+128.5%-26.1%$1.37B$605.22M-8.081,488Positive NewsSSIISS Innovations InternationalN/A$6.14-12.3%N/AN/A$1.36B$20.65M0.004Gap DownHigh Trading VolumeCDRECadre2.8814 of 5 stars$31.83-0.5%$31.50-1.0%-5.7%$1.30B$567.56M33.862,284Positive NewsBLFSBioLife Solutions2.7697 of 5 stars$26.22-0.9%$31.29+19.3%+15.3%$1.27B$93.47M-218.48440Positive NewsESTAEstablishment Labs2.3021 of 5 stars$38.24-2.0%$56.50+47.8%-7.8%$1.13B$166.02M-12.541,018Positive NewsMDXGMiMedx Group3.523 of 5 stars$7.17+0.4%$12.00+67.4%+15.3%$1.06B$348.88M34.14870Positive NewsPLSEPulse Biosciences4.1347 of 5 stars$15.04-0.5%$22.00+46.3%-11.9%$1.02B$700K-14.32140Positive NewsINMDInMode2.8863 of 5 stars$15.28+2.0%$18.04+18.1%-9.2%$946.87M$401.56M6.19480Positive NewsIRMDiRadimed4.817 of 5 stars$71.85-0.2%$72.00+0.2%+58.9%$915.36M$73.24M44.35110Positive NewsShort Interest ↓BBNXBeta Bionics1.0921 of 5 stars$23.13+14.5%$22.56-2.5%N/A$878.10M$65.12M0.00294High Trading Volume Related Companies and Tools Related Companies NovoCure Competitors SS Innovations International Competitors Cadre Competitors BioLife Solutions Competitors Establishment Labs Competitors MiMedx Group Competitors Pulse Biosciences Competitors InMode Competitors iRadimed Competitors Beta Bionics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DCTH) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Delcath Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Delcath Systems With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DCTH Stock Alerts